Who should read this?
People with muscle-invasive bladder cancer who are fit for cisplatin chemotherapy and are considering treatment before surgery, and possibly after surgery.
Which cancer is this about?
Muscle-invasive bladder cancer treated with neoadjuvant cisplatin and gemcitabine, followed by radical cystectomy, with peri-operative durvalumab in the experimental arm.
Why this matters
Neoadjuvant cisplatin-based chemotherapy improves cure rates, but a significant risk of recurrence remains. NIAGARA tested whether adding immunotherapy around the time of surgery could improve long-term cancer control and survival.
Treatment studied
The trial compared:
• Durvalumab given peri-operatively with gemcitabine/cisplatin, then continued after surgery
versus
• Gemcitabine/cisplatin followed by surgery alone
(Exact schedules varied by protocol and reporting.)
Results
Event-free survival:
Reported hazard ratio around 0.68 (95% CI 0.56–0.82), consistent with a meaningful reduction in recurrence or death events.
Overall survival:
Reported hazard ratio around 0.75 (95% CI 0.59–0.93) in published analyses.
(Another conference report described a similar reduction in recurrence or death after cystectomy, with a hazard ratio of 0.69.)
Key takeaway
For people with muscle-invasive bladder cancer who are eligible for cisplatin, adding peri-operative durvalumab to standard chemotherapy improves cancer control and appears to improve survival compared with chemotherapy and surgery alone.
The decision involves balancing this added benefit against extra immunotherapy visits and the risk of immune-related side effects, and should be individualised.